Amryt Pharma plc

DB:3N9A Stock Report

Market Cap: €851.4m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Amryt Pharma Valuation

Is 3N9A undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 3N9A when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 3N9A (€12.9) is trading above our estimate of fair value (€6.04)

Significantly Below Fair Value: 3N9A is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 3N9A?

Key metric: As 3N9A is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 3N9A. This is calculated by dividing 3N9A's market cap by their current revenue.
What is 3N9A's PS Ratio?
PS Ratio3.9x
SalesUS$243.62m
Market CapUS$940.67m

Price to Sales Ratio vs Peers

How does 3N9A's PS Ratio compare to its peers?

The above table shows the PS ratio for 3N9A vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.6x
DMP Dermapharm Holding
1.8x3.8%€2.1b
PSG PharmaSGP Holding
2.8x7.3%€321.3m
93M1 MPH Health Care
0.9x-60.2%€96.8m
B8FK Biofrontera
0.8xn/a€15.1m
3N9A Amryt Pharma
3.9x26.3%€940.7m

Price-To-Sales vs Peers: 3N9A is expensive based on its Price-To-Sales Ratio (3.9x) compared to the peer average (2.6x).

Price to Sales Ratio vs Industry

How does 3N9A's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?

17 CompaniesPrice / SalesEstimated GrowthMarket Cap
3N9A 3.9xIndustry Avg. 3.4xNo. of Companies22PS03.67.210.814.418+
17 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 3N9A is good value based on its Price-To-Sales Ratio (3.9x) compared to the European Pharmaceuticals industry average (4.1x)

Price to Sales Ratio vs Fair Ratio

What is 3N9A's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

3N9A PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.9x
Fair PS Ratio6.6x

Price-To-Sales vs Fair Ratio: 3N9A is good value based on its Price-To-Sales Ratio (3.9x) compared to the estimated Fair Price-To-Sales Ratio (6.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 3N9A forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
€18.88
0%
30.1%€24.57€13.20n/a2
Feb ’26n/a
€18.88
0%
30.1%€24.57€13.20n/a2
Jan ’26n/a
€18.88
0%
30.1%€24.57€13.20n/a2
Dec ’25n/a
€18.88
0%
30.1%€24.57€13.20n/a2
Nov ’25n/a
€18.88
0%
30.1%€24.57€13.20n/a2
Oct ’25n/a
€18.88
0%
30.1%€24.57€13.20n/a2
Sep ’25n/a
€18.88
0%
30.1%€24.57€13.20n/a2
Aug ’25n/a
€18.88
0%
30.1%€24.57€13.20n/a2
Jul ’25n/a
€18.88
0%
30.1%€24.57€13.20n/a2
Jun ’25n/a
€18.88
0%
30.1%€24.57€13.20n/a2
May ’25n/a
€18.88
0%
30.1%€24.57€13.20n/a2
Apr ’25n/a
€18.88
0%
30.1%€24.57€13.20n/a2
Mar ’25n/a
€18.88
0%
30.1%€24.57€13.20n/a2
Feb ’25n/a
€18.88
0%
30.1%€24.57€13.20n/a2
Jan ’25n/a
€18.88
0%
30.1%€24.57€13.20n/a2
Dec ’24n/a
€18.88
0%
30.1%€24.57€13.20n/a2
Nov ’24n/a
€18.88
0%
30.1%€24.57€13.20n/a2
Oct ’24n/a
€18.88
0%
30.1%€24.57€13.20n/a2
Sep ’24n/a
€18.88
0%
30.1%€24.57€13.20n/a2
Aug ’24n/a
€18.88
0%
30.1%€24.57€13.20n/a2
Jul ’24n/a
€18.88
0%
30.1%€24.57€13.20n/a2
Jun ’24n/a
€18.88
0%
30.1%€24.57€13.20n/a2
May ’24n/a
€18.88
0%
30.1%€24.57€13.20n/a2
Apr ’24€12.80
€17.11
+33.7%
28.2%€25.32€13.60n/a4
Mar ’24€13.10
€16.15
+23.3%
27.5%€24.85€13.34n/a5
Feb ’24€12.90
€16.15
+25.2%
27.5%€24.85€13.34n/a5

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/04/14 12:38
End of Day Share Price 2023/04/11 00:00
Earnings2022/09/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Amryt Pharma plc is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michelle GilsonCanaccord Genuity
Brandon FolkesCantor Fitzgerald & Co.
Andrew YoungDavy